

Lukas Kenner

Personal Data:

Place of Birth: Erlangen, Germany
Date of Birth: October 8, 1965
Nationality: Austrian
Acad. Degree: Univ. Prof. Dr. MD
Current Position: Full Professor; Medical University Vienna, University of Veterinary Medicine Vienna, Deputy Director Ludwig Boltzmann Institute for Cancer Research, Vienna, Deputy Director Clinical Institute for Pathology (CIP), Medical University Vienna (MUW)
Address: Medical University Vienna, Waehringer Guertel 18-20, A-1090 Vienna
www.vetmeduni.ac.at; <http://lbicr.lbg.ac.at/en>;
<http://www.meduniwien.ac.at/orgs/index.php?id=1884>

ORCID ID: 0000-0003-2184-1338

Scientific Education and Career History:

Oct-Dec 2016	Interim Director Clinical Institute for Pathology (CIP), Medical University Vienna
Since 2015	Deputy Director Clinical Institute for Pathology (CIP), Medical University Vienna
since 2014	§98 / full professorship, Department for Experimental Pathology and Laboratory Animal Pathology Medical University Vienna and University of Veterinary Medicine Vienna
since 2005	Group leader and deputy Director (since 2012) at the Ludwig Boltzmann Institute for Cancer Research, Vienna; LBI-CR Renewal and second funding period with five Partner Institutions. Associate Professor for Pathology at the Clinical Institute of Pathology, MUW, Vienna
2001-2004	Head of the Histology Lab (IMP) and Post-doctoral fellow, Institute for Molecular Pathology (IMP) with Prof. Erwin F. Wagner, Vienna, Austria
2000	Post-doctoral position with Specialisation in Haematopathology at the Pathology Institute, Free University Berlin with Prof. H. Stein
1992 - 2001	Training in Pathology and Board registration (2001) and Habilitation (<i>Venia docendi</i>), Medical Faculty, Graz, Austria (2001)
1986 - 1991	Study of Medicine at the University Graz, Graz, Austria, MD Degree 1991

Most important awards, recent 5 years:

2015	Novartis Prize of the German Society of Pathology (DGP)
2013	Novartis Prize of the German Society of Pathology (DGP)
2013	Prize of the Central European Society for Anticancer Drug Research (CESAR) for discovering a novel therapeutic strategy for highly malignant T-cell Lymphomas
2011	Science and Innovations prize of the German Society for Hematology and Oncology (DGHO)
2010	Rokitansky award of the Austrian Society of Pathology

Most important invitations to present at scientific conferences, recent 5 years:

Host	Institute/Conference	Date
Pernille Hojman	"Transcription factors in tumorigenesis: from ALCL to prostate cancer", The Royal Danish Academy of Sciences and Letters, Symposium: Molecular Mechanisms linking Exercise and Cancer. Invited speaker	6/16
Suzanne Turner	"PDFGR inhibitors and therapy of ALCL", The Inaugural UK Paediatric Lymphoma Meeting, Hughes Hall, Cambridge. Invited speaker, CRUK Kids and Teens Invited Lecture	4/16
James Darnell, David Levy, George Stark	"STAT3 in Cancer: How can it be inhibited?", Banbury Center of Cold Spring Harbor Laboratory, Meeting. Invited speaker, Plenary Talk	3/16
Suzanne Turner	"Transcription factors in oncogenesis: from ALCL to prostate cancer", Cellular Genetic Disease Seminar, University Cambridge, Department of Pathology. Invited speaker	1/15
Tadamitsu Kishimoto/ Stefan Rose-John	"Interleukin 6: Biology-Pathophysiology-Therapy", Mid-Term Conference of the International Cytokine and Interferon Society (ICIS), Kiel, Germany. Invited speaker, Plenary Talk	5/14
Bente Klarlund Pedersen	8th Conference of Centre of Inflammation and Metabolism (CIM), Copenhagen, Denmark, Invited speaker, Plenary Talk	5/14
Stefan Rose-John	4 th cluster, Symposium Inflammation and Interfaces, Hamburg, Germany. Invited speaker, Key Note Lecture	2/13

5 most important review activities:

Deutsche Forschungsgemeinschaft (DFG, Germany)
Israel Science Foundation (ISF)
Prostate Cancer UK
Bioethikkommission of the Austrian Chancellor at the Bundeskanzleramt
Sachverständiger für den Deutschen Bundestag
Editorial Board of Molecular Cancer, Associate Editor

Research Interest:

<ul style="list-style-type: none"> • AP-1 and JAK-STAT signaling and core cancer pathways • Basic and translational cancer research with a main focus on comparative pathology in human patient samples compared to gene targeted mouse models to explore new diagnostic approaches facilitating digital pathology procedures for establishing new therapies
--

Publications:

Original papers: 126 (cumulative IF: 1272.3; Peer-reviewed reviews & Book Chapters: 15); H-Factor: 41; Invited lectures: >200; Patents: 2

Major Recent Research Grants:

1. Co-Coordinator of the ALKATRAS ITN network, 2015-2019 (~1.2 Mill €/year)
2. Basic Funding of the LBI-CR: Ludwig Boltzmann Society (LGB) and five Partner organisations (Medical University Vienna, Institute of Molecular Pathology, Children's Cancer Research Center, Tissue Gnostics, Veterinarian University Vienna), 2005-2019, <http://lbicr.lbg.ac.at/en>; (~1.2 Mill €/year)
3. CBMed GmbH (Ltd.), 2016-2018, CORE-LAB 2 for Target Identification and Probe Development (TIP); PI (~376k €/year)
4. Austrian Science Funds: FWF-P 29251-B28, 2016-2019, PDGFRB function in lymphoma progression; PI (~120k €/year)
5. Oncotyrol, extension, 2016-2017, Role of Medium-Chain Triacylglycerols in Prostate cancer development, Deputy coordinator and subproject; PI (~20k €)
6. Buergermeisterfonds, Proj. Nr. 15142, 2016-2017, Zirkulierende Tumorzellen als Biomarker im kastrationsresistenten Krebs der Prostata; PI (10k €)
7. Margaretha Hehberg Foundation of the Buergermeisterfonds, Proj. Nr. 15142, 2016-2017, Zirkulierende Tumorzellen als Biomarker im kastrationsresistenten Krebs der Prostata; PI (10k €)
8. Austrian Science Funds: FWF-P 26011, 2013-2016, Genetic dissection of IL-6 signalling in prostate tumourigenesis; PI (~110k €/year)
9. Jubiläumsfonds / Austrian Nationalbank, 2013-2016, MicroRNAs in nodal T-cell lymphomas: Molecular signatures and therapeutic Approaches, Co-PI (~35k €/year)

Collaborations

International (in alphabetical order with brief topic link):

Vincent **Goffin**; Inserm U1151 / Institut Necker Enfants Malades (INEM), Paris, F.

Stephan **Mathas**, Charité, Berlin, Germany

Bente **Klarlund**, Rigshospitalet, University of Copenhagen, DK

Stephan **Rose-John**, Christian-Albrechts-Universität zu Kiel, Germany

Sebastian **Bauer**; University Duisburg-Essen, Germany; GIST mutations of c-KIT in human GIST tumour formation

Fabrice **Gouilleux**; University Picardie Jules Verne, INSERM, Amiens, France; GIST and activated forms of Stat3

Greg **Hannon**; Cold Spring Harbor Laboratory (CSHL), USA; miRNA in cord blood stem cell differentiation

Konrad **Hochedlinger**; Harvard Stem Cell Institute, Cambridge, MA, U.S.A.; Stem cell induction using viral vectors

Giorgio **Inghirami**; Cornell University, NY, USA; AP-1 in NPM-ALK induced human- and mouse lymphomagenesis

Richard **Kennedy**; Queens University Belfast, UK; Stat3 and IL-6 pathway analysis in prostate cancer

Tom **Look**; Dana **Farber**, Boston, USA; ALCL and mutated JAK kinases

Colin **McGuckin**; CTI, Lyon, France; Jak/Stat pathway in stem cell differentiation and tumourigenesis

Mark **Parthun**; Ohio State University, Columbus, USA; Characterisation of HAT-/- mouse models

Mariusz **Ratajczak**; University of Louisville, Stem cell Institute at James Brown Cancer Center, KY, USA; Cancer stem cell induced rhabdomyosarcoma development

Raffaella **Sordella**; CSHL, USA; IL-6 in lung carcinogenesis

Karel **Soucek**; Institute of Biophysics ASCR, Brno, Czech Republic; stem cells in Prostate cancer

William **Tse**; West Virginia University School of Medicine, Morgantown, USA; AF1q in breast cancer metastasis

Jan **Tuckermann**; University of Ulm, Germany; Transgenic Stat5 and GR mice in inflammatory diseases

Suzanne **Turner**; University of Cambridge UK; Tumour – stroma interactions and stem cell pathology in ALCL

A handwritten signature in blue ink, appearing to be 'Lukas Kenner', written in a cursive style.